Maron et al. demonstrated that combination of two antibodies targeting HER1 and HER2 impairs receptors dimerization, enhances receptors degradation and synergizes in tumor growth inhibition in preclinical models [16]. The gene discussed is ERBB2; the disease is neoplasm.